Download video

Clinical Trial: MK-0482 for Tumors (NCT03918278)

12 views

Power Life Sciences

2 years ago

Clinical Trial: MK-0482 for Tumors (NCT03918278)

Clinical Trial: MK-0482 for Tumors (NCT03918278)

Clinical Trial: MK-0482 for Tumors (NCT03918278)
4:09
Clinical Trial: MK-0482 for Tumors (NCT03918278)
by Power Life Sciences
CIRM Clinical Trial (CLIN2) Awards Informational Webinar - May 2025
51:44
CIRM Clinical Trial (CLIN2) Awards Informational Webinar - May 2025
by California Institute for Regenerative Medicine
Clinical Trials
0:29
Clinical Trials
by Willis Knighton Health
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea...
32:07
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Brea...
by Medscape
Medicine (90281-99607) I Special Otorhinolaryngologic Services (92502-92700) I
9:25
Medicine (90281-99607) I Special Otorhinolaryngologic Services (92502-92700) I
by MECOpedia
Linvoseltamab+Carfilzomib in Relapsed\/Refractory Multiple Myeloma: LINKER-MM2 Trial Initial Results
7:31
Linvoseltamab+Carfilzomib in Relapsed\/Refractory Multiple Myeloma: LINKER-MM2 Trial Initial Results
by International Myeloma Foundation
Results from the CARTITUDE-1 Study in Patients With Multiple Myeloma
7:01
Results from the CARTITUDE-1 Study in Patients With Multiple Myeloma
by CheckRare
The Road to a Successful Inspection - What’s Being Inspected and Why It Matters - Part 2
17:26
The Road to a Successful Inspection - What’s Being Inspected and Why It Matters - Part 2
by GCP-Mindset - All About Clinical Research
The Battle for Clinical Training Sites
13:01
The Battle for Clinical Training Sites
by Sheriff of Sodium
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
2:18
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
by VJHemOnc – Video Journal of Hematology \& HemOnc
Current Clinical Trials in the U.S.
58:50
Current Clinical Trials in the U.S.
by Leptomeningeal Cancer Foundation
PF-07220060, a novel oral CDK4-selective inhibitor, in HR+\/HER2- mBC
3:41
PF-07220060, a novel oral CDK4-selective inhibitor, in HR+\/HER2- mBC
by VJOncology
Pyrilutamide (KX826) Officially Released: Good News?
10:39
Pyrilutamide (KX826) Officially Released: Good News?
by KwRx 🕊️
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
1:11
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Clinical Evaluation 2
1:35:13
Clinical Evaluation 2
by Brian McCollough